Eli Lilly continues to dominate the obesity market with Zepbound and Orforglipron, leading JPMorgan to see it as a top pick ...

Eli Lilly ( LLY 0.90%) is one of the undisputed leaders in the fast-growing market for weight-management medicines. Following ...

Eli Lilly expands Zepbound access with flat-rate pricing and new vial options, supporting wider obesity treatment access ...

Although Novo was first to market with Wegovy and its sister ... The company is also studying Zepbound’s impact on illness and death in a trial that’s due to deliver results in 2027.

Researchers compared the safety and efficacy of tirzepatide (brand name Zepbound) and semaglutide ... While the study primarily looked at the impact of the medications, experts agreed there ...